症状性动脉粥样硬化性非急性颅内大动脉闭塞治疗进展  

Research progress on treatment of symptomatic atherosclerotic non-acute intracranial arterial occlusion

作　　者：张会军 吕清 张允[1] 姚胜旗[1] 王晓平[1] ZHANG Huijun;LYU Qing;ZHANG Yun;YAO Shengqi;WANG Xiaoping(Department of Neurology,Tongren Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200336,China)

机构地区：[1]上海交通大学医学院附属同仁医院神经内科,上海200336

出　　处：《世界临床药物》2021年第7期523-527,共5页World Clinical Drug

摘　　要：颅内动脉粥样硬化性非急性大动脉闭塞是导致缺血性脑卒中的重要原因之一,缺血性脑卒中常导致严重残疾或认知功能和情感障碍,给患者和社会带来沉重的经济负担。既往研究尝试颅内外动脉搭桥治疗颅内动脉粥样硬化性闭塞.但是由于较高的围手术期风险、技术要求以及入选患者的严格适应证,其临床应用受限。近年来,一些小样本、单中心的研究表明,血管内治疗可能成为治疗颅内动脉粥样硬化性闭塞的可选择手段,但缺乏大样本、多中心、随机对照研究证据的支持。目前针对症状性动脉粥样硬化性非急性颅内大动脉闭塞,专家共识建议还是以内科药物治疗为主。Symptomatic atherosclerotic non-acute intracranial arterial occlusion is one of the important causes of ischemic stroke,which often leads to severe disability or cognitive and emotional disorders,and brings heavy economic burden to patients and society.Previous studies have tried to treat these patients with intracranial and extracranial artery bypass grafting,but its clinical application is limited due to its high perioperative risk,high technical requirements and strict indications of enrolled patients.In recent years,some small sample,single-center studies have shown that endovascular treatment may become an alternative method for the treatment of intracranial atherosclerotic occlusion,but there is a lack of evidence support from large sample,multi-center,randomized controlled studies.Therefore,the current consensus of experts on symptomatic atherosclerotic non-acute intracranial arterial occlusion suggests that standard medical therapy should be given priority to.

关 键 词：动脉粥样硬化性非急性颅内大动脉闭塞:血管内治疗:药物治疗 

分 类 号：R743[医药卫生—神经病学与精神病学]